New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug ...
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to ...
Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while ...
Leerink notes that Amgen’s Phase 2 MariTide showed “up to ~20% average weight loss at 52 weeks” in nondiabetic obese/overweight patients, which is roughly on par with the hi ...
Investor's Business Daily on MSN2h
Amgen Crashes 9% Despite 'Truly Remarkable' Results For Obesity TreatmentAmgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even ...
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter James Shin has given his Hold rating due to a combination of factors affecting Amgen’s recent performance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback